Nubeqa (darolutamide)

pCPA File Number: 22191

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel

Sponsor/Manufacturer:

Bayer Inc.

CDA-AMC Project Number:

PC0294-000

pCPA Engagement Letter Issued:

2023-09-20

Negotiation Process Concluded:

2023-11-01